Key Insights

Highlights

Success Rate

80% trial completion

Published Results

12 trials with published results (41%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

17.2%

5 terminated out of 29 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

41%

12 trials in Phase 3/4

Results Transparency

60%

12 of 20 completed with results

Key Signals

12 with results80% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (4)
P 1 (4)
P 2 (4)
P 3 (4)
P 4 (8)

Trial Status

Completed20
Terminated5
Unknown3
Enrolling By Invitation1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT07330440Phase 1Enrolling By InvitationPrimary

A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination

NCT06033261Phase 1CompletedPrimary

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

NCT01658826Phase 2TerminatedPrimary

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

NCT00495716Phase 4TerminatedPrimary

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

NCT05500053CompletedPrimary

A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease

NCT05675228UnknownPrimary

Knowledge of Young Adults About Genital Herpes

NCT04222985Phase 1TerminatedPrimary

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2

NCT03595995Phase 2UnknownPrimary

A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

NCT03831165Phase 4CompletedPrimary

Melatonin Effects on Genital Herpes in Brazilian Women

NCT00362297Phase 4CompletedPrimary

Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT01281007Phase 3CompletedPrimary

Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes

NCT03080961Not ApplicableCompleted

The VIBLOK SAfety and perFormancE Trial

NCT03146403Phase 2TerminatedPrimary

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT00527618Phase 4CompletedPrimary

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

NCT01132716Not ApplicableCompleted

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions

NCT01132729Not ApplicableCompleted

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

NCT01390805CompletedPrimary

Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)

NCT01346475Phase 4CompletedPrimary

Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT00723229Phase 4CompletedPrimary

A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation

NCT01765114Phase 2TerminatedPrimary

A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes

Scroll to load more

Research Network

Activity Timeline